Aviado · Research
Longevity Daily
Thursday, August 27, 2026
Listen
Today's Brief
Today's digest is anchored by a paradigm-shifting NYT piece on "intrinsic capacity" — the WHO-backed composite metric poised to become the gold standard for proving whether longevity interventions actually work. A sweeping Nature Medicine analysis finds that more than half of 51 tested interventions moved no aging clock at all, challenging the assumptions behind a multibillion-dollar supplement market. Elsewhere, new large-study data shows HRT cuts Alzheimer's risk by 16% in women, and an approved Japanese diabetes drug quietly reverses muscle loss in aging mice — tackling a condition with zero approved treatments worldwide.
10 stories1 trials1 Aviado original
Cognitive Health & Neuroprotection
HRT Users Are 10–16% Less Likely to Develop Dementia, Large Study Finds
A large observational study found that women who used hormone replacement therapy were 10% less likely to develop any form of dementia — and 16% less likely to develop Alzheimer's disease specifically — compared with non-users. The findings add substantial weight to the case for HRT as a cognitive-protective intervention, not merely a menopause symptom reliever. The data is observational, so confounders can't be fully excluded, but the magnitude of effect across both dementia categories is hard to dismiss.
Read more →Sam Altman-Backed Retro Biosciences Doubles Down on Alzheimer's Drug After Early Trial Setback
Retro Biosciences — the longevity company seeded with $180 million by Sam Altman — is escalating to higher doses of its lead Alzheimer's candidate RTR-242 after Phase 1 results disappointed. The drug targets lysosomes, the cellular recycling plants that turn sluggish and acidic with age, allowing toxic debris to accumulate in neurons. Experts describe the lysosome as a genuinely promising target for cognitive decline, but note that no drug using this approach has cleared the clinical bar yet.
Read more →Supplements & Compounds
Most Longevity Interventions Don't Move the Aging Clock — And Senolytics Go Both Ways
A sweeping review of 51 longevity interventions, covered by Medical Daily citing a Nature Medicine analysis, found that more than half failed to measurably shift any epigenetic aging clock. Senolytics — drugs designed to clear 'zombie' senescent cells — were especially confounding: different studies showed them moving clocks in opposite directions. If your supplement stack is built on aging-clock marketing, this is the sobering reality check the field has been waiting for.
Read more →L-BAIBA: The Exercise Molecule That Controls How Hard Your Body Responds to Training
New research from Fight Aging! reveals the biochemical mechanism behind L-BAIBA, a signaling molecule released by muscle cells during exercise that tells the body how vigorously to amplify training benefits. In aged mice, higher L-BAIBA levels enhanced both muscle and bone responses to physical activity — and researchers have now mapped the pathway that drives this effect. This is animal data, so temper expectations, but for anyone focused on maximizing the return on exercise, L-BAIBA is a compound worth tracking.
Read more →Research & Papers
'Intrinsic Capacity': The Most Important Longevity Metric You've Never Heard Of
The WHO's concept of 'intrinsic capacity' — a composite score spanning cognition, mobility, vitality, sensory function, and psychological wellbeing — may be the most consequential number in aging that most people have never encountered. Unlike single biomarkers or biological age clocks, it tracks your functional reserve across five systems simultaneously, offering a richer picture of how well you're actually aging rather than how old you look on paper. Longevity scientists believe it could become the definitive endpoint for proving whether drugs, supplements, or lifestyle interventions genuinely slow aging — the clinical infrastructure the field has long been missing. Your doctor can't test it yet, but that's likely to change soon.
Read more →Your Organs Are Aging at Wildly Different Rates — And AI Can Detect It From Blood
AI-powered 'tissue clocks' trained on human tissue architecture reveal that organs within the same body age on strikingly different timelines — your brain, heart, and liver may be at dramatically different biological ages simultaneously. Critically, some of these organ-specific aging patterns can be detected from a standard blood draw, pointing toward a near future where routine bloodwork pinpoints which of your systems is racing ahead of the others. This adds meaningful nuance to the fast-growing world of biological age testing.
Read more →Aviado Research: Deep Dive Into Longevity Science and Aging Interventions
Aviado Research's latest original analysis explores key developments across the longevity science landscape, offering in-depth expert commentary and evidence-based guidance on aging interventions. Read the full piece for Aviado's independent take on what the latest research means for your health optimization practice.
Read the full Aviado analysis →Lifestyle & Nutrition
Forget BMI: A Simple Waist Measurement Predicts Longevity Better in Older Adults
A new study finds that waist circumference outperforms BMI as a predictor of longevity in older adults — excess abdominal fat carries elevated mortality risk even in people with a 'normal' BMI score. The finding reinforces that where you carry weight matters as much as how much you carry, and that BMI may be creating a false sense of metabolic security for millions. Measuring your waist takes 30 seconds; it may be the most useful number you're not currently tracking.
Read more →Metformin Adds No Functional Benefit on Top of Lifestyle Changes for Older Adults
A rigorous clinical study found that intensive diet-and-exercise intervention significantly improved physical function, cardiorespiratory fitness, muscle strength, and quality of life in older adults with obesity and functional impairment. Adding metformin to the program delivered zero additional functional benefit beyond what lifestyle changes achieved alone. For the many longevity enthusiasts who take metformin as a default hedge alongside a healthy routine, this raises a pointed question: what, exactly, are you getting out of it?
Read more →An Approved Diabetes Drug Just Preserved Muscle Mass in Aging Mice — Could It Treat Sarcopenia?
Imeglimin, a first-in-class antidiabetic already licensed in Japan under the name Twymeeg, preserved skeletal muscle mass and strength in two independent mouse models of age-related muscle loss. This matters because sarcopenia — the progressive muscle wasting that accelerates after 60 — has no approved drug treatment anywhere in the world. The mechanism involves mitochondrial pathways distinct from metformin, making imeglimin a genuinely novel candidate; human trials are the essential next step.
Read more →